Caris Life Sciences

Caris Molecular Intelligence is distinguished by its routine clinical use of Whole Exome Sequencing and Whole Transcriptome Sequencing across all solid tumors, which generates protein, DNA, and RNA data layers from a single biopsy. This high-dimensional approach feeds into a proprietary rules engine that ranks therapeutic options, including on- and off-label drugs, as well as clinical trials. A 2020 study in JAMA Oncology (per the Journal of the American Medical Association, 2020) suggested that patients whose therapy matched the genomic alterations identified by such comprehensive profiling had a significantly longer time to next treatment than unmatched patients.

Caris operates a dual revenue model. The clinical division generates direct revenue by performing molecular testing on patient tumor samples, which is reimbursed by payers. In parallel, its CODEai business licenses de-identified, linked clinico-genomic data and analytics services to biopharma partners. These pharmaceutical companies use the data for biomarker discovery, patient sub-population identification, and clinical trial support, creating a data-as-a-service revenue stream that sits apart from diagnostic testing fees.

Caris Life Sciences is a privately held company. It raised $830 million in a growth equity round in 2021 led by TPG and joined by Dragoneer and existing investor OrbiMed, placing its valuation above $7 billion at the time (per Forbes and Reuters, 2021). The company has also secured significant term loan financing from groups including Sixth Street to fund continued expansion without going public.

CODEai ingests the company's massive multi-modal data lake — constituting whole-exome, whole-transcriptome, and proteomic profiles linked to longitudinal clinical outcomes from over 400,000 cases. The platform applies machine learning and AI-based algorithms to derive biological insights that are not apparent from a single data layer. In a 2025 expansion, Caris partnered with Molecular Methods to integrate the AiONE AI platform, aiming to accelerate bioinformatics workflows and deep learning model development for novel cancer biomarker identification (per PR Newswire, 2025).

Caris has disclosed multiple collaborations with major biopharmaceutical firms. In 2024, it signed a strategic partnership with Merck KGaA to accelerate oncology drug development using its clinico-genomic data and analytics. A prior multi-year partnership with Bristol Myers Squibb, established in 2022, focused on leveraging Caris's platform to support targeted oncology programs. These relationships typically involve collaborative research into novel drug targets, biomarker validation, and clinical trial candidate identification.

The company's clinical testing and logistics hub is a large, ISO 15189-certified laboratory in Phoenix, Arizona, which processes thousands of oncology specimens each month. Its corporate headquarters is in Irving, Texas. A research and commercialization office in Basel, Switzerland serves as the base for European and international operations, facilitating regulatory engagements and cross-border collaboration with pharmaceutical partners.

David Halbert is the founder, Chairman, and CEO of Caris Life Sciences. Before founding Caris in 2008, he previously founded and served as CEO of AdvancePCS, a pharmacy benefit manager that was sold to Caremark for over $5 billion in 2004. At Caris, he orchestrated the pivot from a diversified laboratory services model to an uncompromising focus on high-dimensional molecular oncology, driving the capital strategy that attracted growth equity from TPG, OrbiMed, and other top-tier healthcare investors.